REPLIGEN CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
REPLIGEN CORP (RGEN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $212.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-07-29
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $212.00K.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $3.92M, a 31.14% decline year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $1.70M, a 19.05% decline year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $8.22M, a 20.91% decline from fiscal 2024.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $10.40M, a 79.31% increase from fiscal 2023.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $5.80M, a 58.87% decline from fiscal 2022.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $14.10M, a 30.54% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $212.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $212.00K 10-Q · filed 2026-07-29 | $4.14M derived: sum of 3 quarters · filed 2026-07-29 | $5.84M derived: sum of 4 quarters · filed 2026-07-29 | ||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 | $3.92M derived: sum of 2 quarters · filed 2026-05-06 | $5.63M derived: sum of 3 quarters · filed 2026-05-06 | $5.63M derived: sum of 4 quarters · filed 2026-07-29 | ||
| 2025-12-31 | $3.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.63M derived: sum of 2 quarters · filed 2026-02-26 | $5.63M derived: sum of 3 quarters · filed 2026-07-29 | $8.22M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.70M derived: sum of 2 quarters · filed 2026-07-29 | $4.30M 10-Q · filed 2025-11-04 | $10.00M derived: sum of 4 quarters · filed 2026-07-29 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $2.60M 10-Q · filed 2026-07-29 | $8.30M derived: sum of 3 quarters · filed 2026-07-29 | $10.40M derived: sum of 4 quarters · filed 2026-07-29 | ||
| 2025-03-31 | $2.60M 10-Q · filed 2026-05-06 | $8.30M derived: sum of 2 quarters · filed 2026-05-06 | $10.40M derived: sum of 3 quarters · filed 2026-05-06 | $11.30M derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-12-31 | $5.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.80M derived: sum of 2 quarters · filed 2026-02-26 | $8.70M derived: sum of 3 quarters · filed 2026-02-26 | $10.40M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.00M derived: sum of 2 quarters · filed 2025-11-04 | $4.70M 10-Q · filed 2025-11-04 | $7.10M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-06-30 | $900.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.60M 10-Q · filed 2025-08-07 | $5.00M derived: sum of 3 quarters · filed 2026-02-26 | $7.70M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | $1.70M 10-Q · filed 2025-04-29 | $4.10M derived: sum of 2 quarters · filed 2026-02-26 | $6.80M derived: sum of 3 quarters · filed 2026-02-26 | $7.30M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $2.40M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-26 | $5.10M derived: sum of 2 quarters · filed 2026-02-26 | $5.60M derived: sum of 3 quarters · filed 2026-02-26 | $5.80M 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $2.70M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | $3.20M derived: sum of 2 quarters · filed 2024-11-18 | $3.40M 10-Q/A · filed 2024-11-18 | $7.70M derived: sum of 4 quarters · filed 2025-03-14 | ||
| 2023-06-30 | $500.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | $700.00K 10-Q/A · filed 2024-11-18 | $5.00M derived: sum of 3 quarters · filed 2025-03-14 | $12.40M derived: sum of 4 quarters · filed 2025-03-14 | ||
| 2023-03-31 | $200.00K 10-Q/A · filed 2024-11-18 | $4.50M derived: sum of 2 quarters · filed 2025-03-14 | $11.90M derived: sum of 3 quarters · filed 2025-03-14 | $12.90M derived: sum of 4 quarters · filed 2025-03-14 | ||
| 2022-12-31 | $4.30M derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-03-14 | $11.70M derived: sum of 2 quarters · filed 2025-03-14 | $12.70M derived: sum of 3 quarters · filed 2025-03-14 | $14.10M 10-K · filed 2025-03-14 | ||
| 2022-09-30 | $7.40M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | $8.40M derived: sum of 2 quarters · filed 2024-11-18 | $9.80M 10-Q/A · filed 2024-11-18 | $15.60M derived: sum of 4 quarters · filed 2024-11-18 | ||
| 2022-06-30 | $1.00M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | $2.40M 10-Q/A · filed 2024-11-18 | $8.20M derived: sum of 3 quarters · filed 2024-11-18 | $16.70M derived: sum of 4 quarters · filed 2024-11-18 | ||
| 2022-03-31 | $1.40M 10-Q/A · filed 2024-11-18 | $7.20M derived: sum of 2 quarters · filed 2024-11-18 | $15.70M derived: sum of 3 quarters · filed 2024-11-18 | $19.20M derived: sum of 4 quarters · filed 2024-11-18 | ||
| 2021-12-31 | $5.80M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | $14.30M derived: sum of 2 quarters · filed 2024-11-18 | $17.80M derived: sum of 3 quarters · filed 2024-11-18 | $20.30M 10-K/A · filed 2024-11-18 | ||
| 2021-09-30 | $8.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $12.00M derived: sum of 2 quarters · filed 2022-11-01 | $14.50M 10-Q · filed 2022-11-01 | $20.40M derived: sum of 4 quarters · filed 2023-02-22 | ||
| 2021-06-30 | $3.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $6.00M 10-Q · filed 2022-08-02 | $11.90M derived: sum of 3 quarters · filed 2023-02-22 | $18.80M derived: sum of 4 quarters · filed 2023-02-22 | ||
| 2021-03-31 | $2.50M 10-Q · filed 2022-04-27 | $8.40M derived: sum of 2 quarters · filed 2023-02-22 | $15.30M derived: sum of 3 quarters · filed 2023-02-22 | $34.40M derived: sum of 4 quarters · filed 2023-02-22 | ||
| 2020-12-31 | $5.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $12.80M derived: sum of 2 quarters · filed 2023-02-22 | $31.90M derived: sum of 3 quarters · filed 2023-02-22 | $36.60M 10-K · filed 2023-02-22 | ||
| 2020-09-30 | $6.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $26.00M derived: sum of 2 quarters · filed 2021-10-28 | $30.70M 10-Q · filed 2021-10-28 | $31.00M derived: sum of 4 quarters · filed 2022-02-17 | ||
| 2020-06-30 | $19.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-27 | $23.80M 10-Q · filed 2021-07-27 | $2.50M 10-Q · filed 2020-07-30 | $24.10M derived: sum of 3 quarters · filed 2022-02-17 | $25.70M derived: sum of 4 quarters · filed 2022-02-17 | |
| 2020-03-31 | $4.70M 10-Q · filed 2021-05-04 | $5.00M derived: sum of 2 quarters · filed 2022-02-17 | $6.60M derived: sum of 3 quarters · filed 2022-02-17 | $10.10M derived: sum of 4 quarters · filed 2022-02-17 | ||
| 2019-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $1.90M derived: sum of 2 quarters · filed 2022-02-17 | $5.40M derived: sum of 3 quarters · filed 2022-02-17 | $5.50M 10-K · filed 2022-02-17 | ||
| 2019-09-30 | $1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $5.10M derived: sum of 2 quarters · filed 2020-11-05 | $5.20M 10-Q · filed 2020-11-05 | $7.00M derived: sum of 4 quarters · filed 2021-02-24 | ||
| 2019-06-30 | $3.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $3.60M 10-Q · filed 2020-07-30 | $5.40M derived: sum of 3 quarters · filed 2021-02-24 | $6.50M derived: sum of 4 quarters · filed 2021-02-24 | ||
| 2019-03-31 | $100.00K 10-Q · filed 2020-05-06 | $1.90M derived: sum of 2 quarters · filed 2021-02-24 | $3.00M derived: sum of 3 quarters · filed 2021-02-24 | $5.20M derived: sum of 4 quarters · filed 2021-02-24 | ||
| 2018-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $2.90M derived: sum of 2 quarters · filed 2021-02-24 | $5.10M derived: sum of 3 quarters · filed 2021-02-24 | $5.30M 10-K · filed 2021-02-24 | ||
| 2018-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $3.30M derived: sum of 2 quarters · filed 2019-10-31 | $3.50M 10-Q · filed 2019-10-31 | |||
| 2018-06-30 | $2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $2.40M 10-Q · filed 2019-08-01 | ||||
| 2018-03-31 | $200.00K 10-Q · filed 2019-05-09 | |||||
| 2017-12-31 | $5.30M 10-K · filed 2020-02-26 | $5.30M 10-K · filed 2018-02-22 | ||||
| 2016-12-31 | $5.00M 10-K · filed 2019-03-01 | $5.04M 10-K · filed 2017-02-23 | ||||
| 2015-12-31 | $3.64M 10-K · filed 2018-02-22 | $4.94M 10-K · filed 2016-02-25 | ||||
| 2014-12-31 | $9.66M 10-K · filed 2017-02-23 | $10.47M 10-K · filed 2015-03-17 | ||||
| 2013-12-31 | $3.72M 10-K · filed 2016-02-25 | |||||
| 2012-12-31 | $1.38M 10-K · filed 2015-03-17 | |||||
| 2012-03-31 | $68.00K derived: 10-K 12 month − 10-K 9 month · filed 2013-03-15 | $76.00K 10-K · filed 2013-03-15 | ||||
| 2011-12-31 | $8.00K 10-K · filed 2014-03-14 | |||||
| 2010-12-31 | $43.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |